LeMaitre Vascular (LMAT) Financials

$97.31 -2.19 (-2.20%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$97.38 +0.07 (+0.07%)

As of 05/15/2026 04:10 PM Eastern

Annual Income Statements for LeMaitre Vascular

This table shows LeMaitre Vascular's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	7.76	11	17	23	18	21	27	21	30	44	58
Consolidated Net Income / (Loss)	7.76	11	17	23	18	21	27	21	30	44	58
Net Income / (Loss) Continuing Operations	7.76	11	17	23	18	21	27	21	30	44	58
Total Pre-Tax Income	11	16	21	28	22	27	34	27	39	57	75
Total Operating Income	12	16	21	28	21	29	36	27	37	52	68
Total Gross Profit	54	63	71	74	80	85	101	105	127	151	179
Total Revenue	78	89	101	106	117	129	154	162	193	220	250
Operating Revenue	78	89	101	106	117	129	154	162	193	220	250
Total Cost of Revenue	24	26	30	32	37	45	53	57	66	69	71
Operating Cost of Revenue	24	26	30	32	37	45	53	57	66	69	71
Total Operating Expenses	43	47	50	46	59	56	65	78	90	99	111
Selling, General & Admin Expense	14	14	17	18	19	23	26	29	32	36	42
Marketing Expense	23	26	26	27	30	24	28	33	41	47	54
Research & Development Expense	5.48	6.14	6.64	8.20	9.28	10	12	13	17	16	14
Restructuring Charge	-	-	-	-	-	0.00	0.00	3.11	0.49	0.00	0.00
Total Other Income / (Expense), net	-0.09	-0.09	0.00	0.24	0.50	-1.43	-2.14	0.66	2.76	4.62	7.27
Interest Expense	-	0.01	0.02	0.00	0.00	1.31	2.22	0.00	0.00	0.21	5.18
Interest & Investment Income	0.01	0.08	0.18	0.63	0.70	0.21	0.20	0.99	3.08	4.95	13
Other Income / (Expense), net	-0.10	-0.16	-0.16	-0.39	-0.20	-0.33	-0.12	-0.33	-0.31	-0.13	-0.64
Income Tax Expense	3.67	5.65	3.93	5.50	3.75	6.14	7.38	6.85	9.37	13	17
Basic Earnings per Share	$0.44	$0.57	$0.91	$1.18	$0.91	$1.05	$1.27	$0.94	$1.36	$1.96	$2.55
Weighted Average Basic Shares Outstanding	17.76M	18.49M	18.96M	19.43M	19.81M	20.25M	21.16M	21.98M	22.22M	22.45M	22.64M
Diluted Earnings per Share	$0.42	$0.55	$0.86	$1.13	$0.88	$1.04	$1.25	$0.93	$1.34	$1.93	$2.52
Weighted Average Diluted Shares Outstanding	18.32M	19.24M	20.03M	20.24M	20.33M	20.48M	21.48M	22.17M	22.42M	22.78M	22.93M
Weighted Average Basic & Diluted Shares Outstanding	17.60M	18.60M	18.90M	18.67M	20.18M	20.53M	21.93M	22.10M	22.34M	22.56M	22.78M
Cash Dividends to Common per Share	$0.16	$0.18	$0.22	$0.28	$0.34	$0.38	$0.44	$0.50	$0.56	$0.64	$0.80

This table shows LeMaitre Vascular's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	7.50	8.47	9.89	12	11	11	11	14	17	16	16
Consolidated Net Income / (Loss)	7.50	8.47	9.89	12	11	11	11	14	17	16	16
Net Income / (Loss) Continuing Operations	7.50	8.47	9.89	12	11	11	11	14	17	16	16
Total Pre-Tax Income	9.83	11	13	16	15	14	14	18	23	20	20
Total Operating Income	9.18	10	12	14	13	13	13	16	20	19	18
Total Gross Profit	31	33	37	38	37	39	41	45	46	46	48
Total Revenue	47	49	53	56	55	56	60	64	61	64	67
Operating Revenue	47	49	53	56	55	56	60	64	61	64	67
Total Cost of Revenue	17	16	17	17	18	17	18	19	15	18	18
Operating Cost of Revenue	17	16	17	17	18	17	18	19	15	18	18
Total Operating Expenses	22	23	25	24	24	26	29	29	26	27	31
Selling, General & Admin Expense	7.74	8.44	9.01	8.82	8.93	9.49	10	10	11	10	12
Marketing Expense	9.67	10	12	11	11	13	14	15	12	13	15
Research & Development Expense	4.22	4.35	4.09	4.28	3.66	3.62	4.10	3.54	2.97	3.53	4.06
Total Other Income / (Expense), net	0.65	1.11	0.92	1.13	1.40	1.17	1.62	1.93	2.26	1.47	1.90
Interest Expense	-	-	0.00	0.00	0.00	-	1.29	1.30	1.30	1.30	1.30
Interest & Investment Income	0.84	0.99	1.00	1.14	1.20	1.61	2.90	2.98	3.86	3.35	3.32
Other Income / (Expense), net	-0.19	0.12	-0.08	-0.01	0.20	-0.24	0.00	0.25	-0.31	-0.58	-0.13
Income Tax Expense	2.32	2.85	2.91	3.68	3.41	2.84	3.23	4.29	5.21	4.72	3.99
Basic Earnings per Share	$0.34	$0.39	$0.44	$0.53	$0.50	$0.49	$0.49	$0.61	$0.77	$0.68	$0.69
Weighted Average Basic Shares Outstanding	22.26M	22.22M	22.37M	22.46M	22.48M	22.45M	22.57M	22.61M	22.66M	22.64M	22.80M
Diluted Earnings per Share	$0.33	$0.38	$0.44	$0.52	$0.49	$0.48	$0.48	$0.60	$0.75	$0.69	$0.68
Weighted Average Diluted Shares Outstanding	22.48M	22.42M	22.57M	22.73M	22.84M	22.78M	22.90M	22.89M	24.39M	22.93M	23.03M
Weighted Average Basic & Diluted Shares Outstanding	22.26M	22.34M	22.45M	22.47M	22.48M	22.56M	22.59M	22.64M	22.69M	22.78M	22.85M
Cash Dividends to Common per Share	$0.14	$0.14	$0.16	$0.16	$0.16	$0.16	$0.20	$0.20	$0.20	$0.20	$0.25

This table details how cash moves in and out of LeMaitre Vascular's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	8.76	-3.16	-5.19	7.22	-15	15	65	5.28	5.14	-0.39	2.63
Net Cash From Operating Activities	11	17	23	20	14	35	35	25	37	44	81
Net Cash From Continuing Operating Activities	11	17	23	20	14	35	35	25	37	44	81
Net Income / (Loss) Continuing Operations	7.76	11	17	23	18	21	27	21	30	44	58
Consolidated Net Income / (Loss)	7.76	11	17	23	18	21	27	21	30	44	58
Depreciation Expense	3.39	3.59	4.06	4.32	5.42	8.40	11	9.43	9.52	9.61	10
Amortization Expense	-	-	-	-	-	-	-	-	0.00	0.06	0.87
Non-Cash Adjustments To Reconcile Net Income	1.36	2.21	2.85	-3.93	3.72	4.47	7.68	9.02	7.68	11	12
Changes in Operating Assets and Liabilities, net	-1.07	0.51	-1.22	-3.83	-13	0.72	-11	-14	-11	-20	0.56
Net Cash From Investing Activities	-3.48	-17	-29	-7.06	-24	-53	-61	-10	-25	-200	-65
Net Cash From Continuing Investing Activities	-3.48	-17	-29	-7.06	-24	-53	-61	-10	-25	-200	-65
Purchase of Property, Plant & Equipment	-2.27	-2.84	-6.42	-3.05	-3.76	-2.98	-4.88	-3.23	-7.27	-6.96	-6.78
Acquisitions	-1.58	-14	0.00	-12	-21	-73	0.00	0.00	-0.90	0.00	-1.90
Purchase of Investments	-	0.00	-23	-20	-23	-2.21	-59	-8.00	-17	-278	-641
Sale and/or Maturity of Investments	-	0.00	0.00	21	24	23	3.00	0.00	0.00	85	585
Net Cash From Financing Activities	1.08	-2.58	0.08	-4.42	-4.62	32	14	-9.23	-7.13	158	-15
Net Cash From Continuing Financing Activities	1.08	-2.58	0.08	-4.42	-4.62	32	92	-9.23	-7.13	156	-15
Repayment of Debt	-	-	-	0.00	0.00	-28	39	0.00	0.00	-3.23	0.00
Repurchase of Common Equity	-0.27	-0.31	-0.78	-0.74	-0.68	-0.57	-0.80	-0.64	-0.85	-1.72	-1.82
Payment of Dividends	-2.85	-3.32	-4.18	-5.45	-6.74	-7.70	-9.34	-11	-12	-14	-18
Issuance of Debt	-	-	-	0.00	0.00	65	-	0.00	0.00	169	0.00
Other Financing Activities, net	-0.65	-0.39	-0.46	-1.20	-2.06	-2.80	-0.40	-1.07	6.17	6.44	5.39
Effect of Exchange Rate Changes	-0.28	-0.27	0.82	-	-	0.91	-	-	-	-0.77	0.86

This table details how cash moves in and out of LeMaitre Vascular's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-1.44	6.22	2.33	-4.33	-1.27	2.88	-0.27	1.84	-1.68	2.75	-1.39
Net Cash From Operating Activities	12	11	5.07	9.63	14	15	9.04	20	29	23	15
Net Cash From Continuing Operating Activities	12	11	5.07	9.63	14	15	9.04	20	29	23	15
Net Income / (Loss) Continuing Operations	7.50	8.47	9.89	12	11	11	11	14	17	16	16
Consolidated Net Income / (Loss)	7.50	8.47	9.89	12	11	11	11	14	17	16	16
Depreciation Expense	2.40	2.44	2.38	2.38	2.43	2.48	2.55	2.65	2.61	2.61	2.62
Amortization Expense	-	-	-	-	-	-	0.21	-	-	0.22	0.22
Non-Cash Adjustments To Reconcile Net Income	2.01	1.77	2.64	2.91	2.11	3.17	2.68	3.70	0.33	3.66	2.82
Changes in Operating Assets and Liabilities, net	-0.09	-1.93	-9.84	-7.50	-1.43	-1.65	-7.41	0.16	7.80	1.09	-6.25
Net Cash From Investing Activities	-9.85	-2.26	-2.36	-11	-13	-174	-4.32	-16	-27	-17	-13
Net Cash From Continuing Investing Activities	-9.85	-2.26	-2.36	-11	-13	-174	-4.32	-16	-27	-17	-13
Purchase of Property, Plant & Equipment	-1.05	-1.28	-1.37	-1.88	-1.67	-2.04	-1.38	-1.34	-2.28	-1.78	-2.78
Acquisitions	-0.47	-	0.00	-	-	-	-0.04	-0.05	-	-1.80	-0.05
Purchase of Investments	-8.33	-0.98	-0.99	-9.13	-11	-257	-2.89	-15	-25	-598	-151
Sale and/or Maturity of Investments	-	-	-	-	-	-	0.00	-	-	-	141
Net Cash From Financing Activities	-3.12	-2.69	0.04	-2.87	-3.15	164	-5.24	-2.76	-2.95	-3.59	-3.22
Net Cash From Continuing Financing Activities	-3.12	-2.69	0.04	-2.87	-3.15	162	-5.24	-2.76	-2.95	-3.59	-3.22
Repurchase of Common Equity	-0.01	-0.67	-0.36	-0.01	-0.00	-1.35	-0.60	-0.00	-	-1.22	-0.46
Payment of Dividends	-3.12	-3.12	-3.59	-3.59	-3.60	-3.60	-4.52	-4.52	-4.54	-4.54	-5.71
Other Financing Activities, net	-	-5.07	3.99	0.73	0.45	-5.17	-0.12	1.76	1.59	2.17	2.95
Effect of Exchange Rate Changes	-	-	-0.42	-	-	-	0.25	0.66	-0.05	0.01	-0.15
Cash Income Taxes Paid	-	-	-	-	-	-	0.28	-	2.20	-	0.69

This table presents LeMaitre Vascular's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	91	102	126	153	188	253	293	310	347	552	616
Total Current Assets	58	59	80	94	92	94	140	162	195	402	468
Cash & Equivalents	27	24	19	26	12	27	14	19	24	26	28
Short-Term Investments	-	-	23	22	21	0.21	56	64	81	274	331
Accounts Receivable	12	13	15	16	17	20	20	22	25	30	34
Inventories, net	15	20	21	27	40	45	46	50	58	65	70
Prepaid Expenses	3.56	1.97	2.61	2.92	3.31	2.62	4.19	6.73	6.38	7.48	5.08
Plant, Property, & Equipment, net	7.02	8.01	12	14	15	15	17	18	22	25	27
Total Noncurrent Assets	25	35	34	45	81	144	136	131	130	125	120
Goodwill	18	23	24	30	40	66	66	66	66	66	66
Intangible Assets	6.34	9.90	8.23	14	25	59	53	47	42	36	33
Noncurrent Deferred & Refundable Income Taxes	1.21	1.40	1.38	1.22	1.08	1.69	1.57	1.75	1.00	1.43	0.76
Other Noncurrent Operating Assets	0.17	0.16	0.18	0.19	15	17	16	17	22	22	21
Total Liabilities & Shareholders' Equity	91	102	126	153	188	253	293	310	347	552	616
Total Liabilities	13	14	17	23	40	80	39	42	49	215	222
Total Current Liabilities	10	10	13	20	21	25	22	25	30	31	36
Accounts Payable	1.37	1.22	1.54	1.73	2.60	2.39	2.34	2.90	3.73	1.76	3.65
Accrued Expenses	8.84	8.80	9.77	16	14	18	16	20	24	25	29
Other Current Liabilities	0.17	0.46	1.88	2.18	4.23	2.73	3.14	2.46	2.50	4.11	3.27
Total Noncurrent Liabilities	2.45	3.94	3.36	3.10	19	55	17	17	19	184	186
Long-Term Debt	-	-	-	-	0.00	36	-	-	0.00	168	169
Noncurrent Deferred & Payable Income Tax Liabilities	1.68	1.94	2.18	0.48	1.18	0.13	0.07	0.07	0.11	0.09	1.74
Other Noncurrent Operating Liabilities	0.77	2.00	1.19	2.61	18	19	17	17	19	16	15
Total Equity & Noncontrolling Interests	78	88	110	130	148	173	254	268	298	337	394
Total Preferred & Common Equity	78	88	110	130	148	173	254	268	298	337	394
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	78	88	110	130	148	173	254	268	298	337	394
Common Stock	82	86	93	99	106	115	182	190	201	214	229
Retained Earnings	8.16	15	28	46	57	71	88	98	115	145	185
Treasury Stock	-8.52	-8.83	-9.61	-10	-11	-12	-12	-13	-14	-16	-17
Accumulated Other Comprehensive Income / (Loss)	-4.05	-4.58	-2.29	-3.90	-4.01	-1.53	-3.44	-6.03	-4.63	-6.18	-2.41

This table presents LeMaitre Vascular's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	302	315	326	334	354	363	377	556	578	598	630
Total Current Assets	153	165	174	182	203	213	227	408	430	452	478
Cash & Equivalents	17	17	19	18	27	22	21	25	27	25	27
Short-Term Investments	63	64	71	79	82	91	103	277	292	318	340
Accounts Receivable	20	25	26	24	30	31	32	35	37	32	36
Inventories, net	48	54	54	56	61	64	65	66	68	71	71
Prepaid Expenses	4.84	4.62	4.08	5.10	3.86	5.22	5.94	4.55	5.72	5.76	4.00
Plant, Property, & Equipment, net	15	19	21	21	22	23	24	25	25	26	29
Total Noncurrent Assets	134	131	131	130	129	127	126	123	122	120	123
Goodwill	66	66	66	66	66	66	66	66	66	66	66
Intangible Assets	48	46	44	43	40	39	37	34	33	32	32
Noncurrent Deferred & Refundable Income Taxes	2.79	1.80	2.08	2.33	0.83	1.03	1.31	1.04	1.46	0.85	0.74
Other Noncurrent Operating Assets	17	18	19	19	22	21	21	21	22	21	25
Total Liabilities & Shareholders' Equity	302	315	326	334	354	363	377	556	578	598	630
Total Liabilities	41	41	43	45	45	44	46	208	215	219	223
Total Current Liabilities	23	24	26	29	27	25	29	25	31	33	33
Accounts Payable	2.85	3.37	3.52	4.37	3.09	2.00	1.65	2.18	4.91	3.47	4.18
Accrued Expenses	17	18	19	22	21	21	23	20	23	27	25
Other Current Liabilities	3.19	2.91	3.01	2.87	2.60	2.67	4.20	2.64	2.92	2.89	3.92
Total Noncurrent Liabilities	17	17	17	16	19	18	17	184	184	186	190
Long-Term Debt	-	-	-	-	-	-	-	168	168	168	169
Noncurrent Deferred & Payable Income Tax Liabilities	0.06	0.07	0.07	0.07	0.11	0.10	0.11	0.09	0.10	2.09	1.86
Other Noncurrent Operating Liabilities	17	17	17	16	19	18	16	16	16	15	19
Total Equity & Noncontrolling Interests	261	274	284	289	309	320	331	348	363	379	407
Total Preferred & Common Equity	261	274	284	289	309	320	331	348	363	379	407
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	261	274	284	289	309	320	331	348	363	379	407
Common Stock	187	192	197	198	207	209	211	217	221	224	234
Retained Earnings	95	101	106	110	122	130	138	152	161	174	195
Treasury Stock	-13	-13	-13	-13	-14	-14	-14	-16	-16	-16	-18
Accumulated Other Comprehensive Income / (Loss)	-8.13	-5.57	-5.82	-6.71	-5.56	-5.09	-3.16	-5.15	-3.00	-2.91	-3.86

This table displays calculated financial ratios and metrics derived from LeMaitre Vascular's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.20%	13.78%	13.14%	4.66%	11.05%	10.35%	19.37%	4.68%	19.69%	13.63%	13.53%
EBITDA Growth	53.29%	33.51%	26.50%	28.54%	-17.87%	39.61%	28.56%	-24.15%	27.76%	34.60%	27.13%
EBIT Growth	80.44%	41.75%	29.51%	32.78%	-24.57%	35.64%	27.58%	-27.00%	37.33%	43.22%	29.05%
NOPAT Growth	99.07%	36.23%	61.24%	32.48%	-22.98%	27.43%	28.01%	-29.54%	39.02%	44.52%	28.89%
Net Income Growth	98.16%	36.50%	62.20%	33.57%	-21.83%	18.32%	26.80%	-23.31%	45.89%	46.28%	31.10%
EPS Growth	82.61%	30.95%	56.36%	31.40%	-22.12%	18.18%	20.19%	-25.60%	44.09%	44.03%	30.57%
Operating Cash Flow Growth	107.51%	47.72%	35.35%	-14.70%	-27.31%	145.43%	0.87%	-27.70%	44.81%	20.06%	84.14%
Free Cash Flow Firm Growth	284.67%	-130.83%	676.98%	-29.83%	-282.10%	-192.18%	161.13%	-32.82%	9.88%	35.13%	94.83%
Invested Capital Growth	1.85%	25.34%	7.75%	20.76%	40.38%	59.04%	0.31%	0.72%	3.94%	6.49%	-1.12%
Revenue Q/Q Growth	2.35%	3.25%	2.92%	2.16%	1.54%	6.05%	1.28%	0.91%	4.27%	3.21%	3.63%
EBITDA Q/Q Growth	2.93%	3.83%	11.63%	2.98%	-6.33%	17.64%	-1.78%	-4.10%	7.30%	3.92%	9.22%
EBIT Q/Q Growth	3.97%	4.48%	13.24%	2.97%	-8.74%	18.45%	-3.22%	-3.42%	8.88%	4.61%	9.14%
NOPAT Q/Q Growth	7.68%	1.40%	10.41%	8.04%	-8.28%	16.04%	-3.49%	-6.84%	10.31%	6.92%	8.78%
Net Income Q/Q Growth	8.59%	0.64%	10.89%	8.21%	-7.30%	12.87%	-3.09%	-2.59%	10.41%	6.58%	8.25%
EPS Q/Q Growth	5.00%	0.00%	11.69%	7.62%	-7.37%	11.83%	-5.30%	-2.11%	10.74%	5.46%	9.09%
Operating Cash Flow Q/Q Growth	12.19%	1.62%	12.69%	-1.01%	-6.45%	32.61%	-20.58%	-3.71%	22.17%	11.18%	10.88%
Free Cash Flow Firm Q/Q Growth	26.17%	-123.58%	1,323.68%	-13.32%	-1,214.60%	33.98%	-16.94%	-14.75%	35.44%	25.46%	7.11%
Invested Capital Q/Q Growth	-0.25%	21.47%	-0.71%	3.17%	18.52%	-1.32%	1.22%	2.20%	0.63%	-0.89%	-0.61%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	69.13%	70.59%	70.09%	70.04%	68.12%	65.41%	65.65%	64.89%	65.66%	68.63%	71.53%
EBITDA Margin	18.90%	22.17%	24.79%	30.44%	22.52%	28.49%	30.68%	22.23%	23.73%	28.11%	31.48%
Operating Margin	14.69%	18.32%	20.92%	26.72%	18.07%	22.25%	23.59%	16.60%	18.97%	23.77%	27.21%
EBIT Margin	14.56%	18.14%	20.77%	26.35%	17.90%	22.00%	23.51%	16.40%	18.81%	23.71%	26.95%
Profit (Net Income) Margin	9.90%	11.88%	17.03%	21.73%	15.30%	16.40%	17.42%	12.77%	15.56%	20.03%	23.13%
Tax Burden Percent	67.91%	65.20%	81.38%	80.66%	82.73%	77.57%	78.48%	75.07%	76.26%	77.43%	76.79%
Interest Burden Percent	100.11%	100.41%	100.75%	102.26%	103.33%	96.12%	94.43%	103.72%	108.45%	109.10%	111.76%
Effective Tax Rate	32.09%	34.80%	18.62%	19.34%	17.27%	22.43%	21.52%	24.93%	23.74%	22.57%	23.21%
Return on Invested Capital (ROIC)	15.65%	18.74%	26.16%	30.27%	17.73%	14.93%	15.54%	10.90%	14.80%	20.32%	25.54%
ROIC Less NNEP Spread (ROIC-NNEP)	15.91%	18.98%	26.15%	29.84%	16.71%	25.21%	21.24%	10.25%	12.56%	17.31%	22.08%
Return on Net Nonoperating Assets (RNNOA)	-5.02%	-5.94%	-8.74%	-11.15%	-4.84%	-1.70%	-2.93%	-2.99%	-4.16%	-6.46%	-9.74%
Return on Equity (ROE)	10.62%	12.81%	17.41%	19.12%	12.88%	13.23%	12.61%	7.90%	10.64%	13.87%	15.80%
Cash Return on Invested Capital (CROIC)	13.81%	-3.74%	18.70%	11.46%	-15.87%	-30.65%	15.24%	10.18%	10.93%	14.04%	26.67%
Operating Return on Assets (OROA)	13.25%	16.79%	18.36%	19.91%	12.29%	12.90%	13.31%	8.79%	11.08%	11.60%	11.52%
Return on Assets (ROA)	9.01%	11.00%	15.05%	16.42%	10.51%	9.62%	9.86%	6.84%	9.16%	9.80%	9.89%
Return on Common Equity (ROCE)	10.62%	12.81%	17.41%	19.12%	12.88%	13.23%	12.61%	7.90%	10.64%	13.87%	15.80%
Return on Equity Simple (ROE_SIMPLE)	9.96%	12.10%	15.65%	17.62%	12.11%	12.30%	10.59%	7.69%	10.11%	13.06%	0.00%
Net Operating Profit after Tax (NOPAT)	7.82	11	17	23	18	22	29	20	28	40	52
NOPAT Margin	9.98%	11.95%	17.03%	21.55%	14.95%	17.26%	18.51%	12.46%	14.47%	18.40%	20.89%
Net Nonoperating Expense Percent (NNEP)	-0.26%	-0.24%	0.01%	0.42%	1.02%	-10.27%	-5.70%	0.65%	2.24%	3.02%	3.46%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	7.51%	9.40%	8.01%	9.28%
Cost of Revenue to Revenue	30.87%	29.41%	29.91%	29.96%	31.88%	34.59%	34.35%	35.11%	34.34%	31.37%	28.47%
SG&A Expenses to Revenue	17.88%	16.10%	16.86%	16.76%	16.25%	17.39%	16.51%	17.78%	16.45%	16.49%	16.84%
R&D to Revenue	6.99%	6.89%	6.58%	7.76%	7.91%	7.81%	7.64%	8.22%	8.77%	7.12%	5.66%
Operating Expenses to Revenue	54.44%	52.27%	49.17%	43.32%	50.05%	43.16%	42.06%	48.29%	46.69%	44.87%	44.32%
Earnings before Interest and Taxes (EBIT)	11	16	21	28	21	28	36	27	36	52	67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	15	20	25	32	26	37	47	36	46	62	79
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.68	4.99	5.22	3.35	0.46	4.61	4.20	3.71	4.21	6.14	4.68
Price to Tangible Book Value (P/TBV)	5.33	8.06	7.38	5.03	0.82	16.66	7.88	6.38	6.59	8.80	6.25
Price to Revenue (P/Rev)	3.66	4.90	5.68	4.13	0.58	6.14	6.91	6.15	6.48	9.42	7.37
Price to Earnings (P/E)	36.97	41.24	33.36	19.01	3.80	37.46	39.67	48.18	41.64	47.04	31.87
Dividend Yield	1.01%	0.77%	0.74%	1.26%	0.99%	0.97%	0.90%	1.11%	0.99%	0.69%	0.99%
Earnings Yield	2.71%	2.42%	3.00%	5.26%	26.30%	2.67%	2.52%	2.08%	2.40%	2.13%	3.14%
Enterprise Value to Invested Capital (EV/IC)	5.14	6.53	7.80	4.72	0.31	4.39	5.42	4.91	5.96	9.45	8.12
Enterprise Value to Revenue (EV/Rev)	3.31	4.63	5.27	3.68	0.30	6.23	6.46	5.64	5.94	8.82	6.61
Enterprise Value to EBITDA (EV/EBITDA)	17.52	20.87	21.25	12.08	1.35	21.87	21.05	25.37	25.02	31.39	20.99
Enterprise Value to EBIT (EV/EBIT)	22.73	25.50	25.37	13.95	1.69	28.32	27.47	34.39	31.56	37.21	24.52
Enterprise Value to NOPAT (EV/NOPAT)	33.17	38.72	30.94	17.06	2.03	36.09	34.90	45.26	41.02	47.94	31.63
Enterprise Value to Operating Cash Flow (EV/OCF)	22.67	24.41	23.24	19.90	2.50	23.16	28.42	35.92	31.25	43.96	20.30
Enterprise Value to Free Cash Flow (EV/FCFF)	37.58	0.00	43.29	45.06	0.00	0.00	35.60	48.43	55.53	69.41	30.29
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.22	0.00	0.00	0.00	0.50	0.43
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.21	0.00	0.00	0.00	0.50	0.43
Financial Leverage	-0.32	-0.31	-0.33	-0.37	-0.29	-0.07	-0.14	-0.29	-0.33	-0.37	-0.44
Leverage Ratio	1.18	1.16	1.16	1.16	1.23	1.38	1.28	1.15	1.16	1.41	1.60
Compound Leverage Factor	1.18	1.17	1.17	1.19	1.27	1.32	1.21	1.20	1.26	1.54	1.79
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	18.06%	0.00%	0.00%	0.00%	33.22%	30.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	1.19%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	16.87%	0.00%	0.00%	0.00%	33.22%	30.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	81.94%	100.00%	100.00%	100.00%	66.78%	70.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	1.03	0.00	0.00	0.00	2.71	2.15
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.30	0.00	0.00	0.00	-2.14	-2.42
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.96	0.00	0.00	0.00	2.71	2.15
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	1.70	0.00	0.00	0.00	4.15	3.23
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.50	0.00	0.00	0.00	-3.26	-3.65
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	1.59	0.00	0.00	0.00	4.15	3.23
Altman Z-Score	15.46	20.35	23.07	13.74	2.89	7.55	18.41	15.88	17.33	7.68	7.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.61	5.63	6.09	4.76	4.42	3.75	6.41	6.39	6.51	13.14	12.89
Quick Ratio	3.80	3.58	4.30	3.22	2.36	1.85	4.11	4.13	4.36	10.77	10.81
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	6.90	-2.13	12	8.61	-16	-46	28	19	21	28	54
Operating Cash Flow to CapEx	506.55%	594.72%	356.37%	638.70%	377.00%	3,628.78%	719.01%	1,070.35%	505.86%	633.78%	1,197.86%
Free Cash Flow to Firm to Interest Expense	0.00	-151.98	584.60	4,307.22	0.00	-34.99	12.63	0.00	0.00	136.33	10.50
Operating Cash Flow to Interest Expense	0.00	1,206.86	1,088.95	9,753.00	0.00	26.56	15.82	0.00	0.00	215.24	15.67
Operating Cash Flow Less CapEx to Interest Expense	0.00	1,003.93	783.38	8,226.00	0.00	25.83	13.62	0.00	0.00	181.28	14.37
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.91	0.93	0.88	0.76	0.69	0.59	0.57	0.54	0.59	0.49	0.43
Accounts Receivable Turnover	6.88	7.09	7.16	6.87	7.26	7.16	7.88	7.76	8.22	7.98	7.84
Inventory Turnover	1.52	1.51	1.49	1.31	1.12	1.06	1.16	1.18	1.23	1.12	1.05
Fixed Asset Turnover	11.27	11.86	9.89	7.97	8.10	8.66	9.62	9.25	9.76	9.45	9.64
Accounts Payable Turnover	19.40	20.30	21.86	19.32	17.24	17.91	22.41	21.65	20.02	25.10	26.29
Days Sales Outstanding (DSO)	53.05	51.51	51.01	53.11	50.27	50.96	46.31	47.05	44.43	45.76	46.56
Days Inventory Outstanding (DIO)	240.85	242.15	245.74	279.47	326.71	345.20	313.85	309.90	297.65	325.52	347.60
Days Payable Outstanding (DPO)	18.81	17.98	16.70	18.90	21.17	20.38	16.29	16.86	18.23	14.54	13.89
Cash Conversion Cycle (CCC)	275.09	275.67	280.05	313.68	355.81	375.78	343.87	340.09	323.84	356.74	380.27
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	50	63	68	82	115	184	184	186	193	205	203
Invested Capital Turnover	1.57	1.57	1.54	1.40	1.19	0.87	0.84	0.87	1.02	1.10	1.22
Increase / (Decrease) in Invested Capital	0.92	13	4.90	14	33	68	0.57	1.32	7.32	13	-2.30
Enterprise Value (EV)	259	412	531	388	36	806	998	912	1,149	1,940	1,649
Market Capitalization	287	437	573	436	68	795	1,067	994	1,254	2,072	1,840
Book Value per Share	$4.30	$4.71	$5.70	$6.65	$74.39	$8.48	$11.64	$12.19	$13.38	$15.00	$17.35
Tangible Book Value per Share	$2.97	$2.92	$4.03	$4.43	$41.83	$2.35	$6.20	$7.08	$8.55	$10.48	$12.98
Total Capital	78	88	110	130	148	211	254	268	298	505	562
Total Debt	0.00	0.00	0.00	0.00	0.00	38	0.00	0.00	0.00	168	169
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	36	0.00	0.00	0.00	168	169
Net Debt	-27	-24	-42	-48	-33	11	-70	-83	-105	-132	-190
Capital Expenditures (CapEx)	2.26	2.84	6.42	3.05	3.76	0.96	4.88	2.37	7.27	6.96	6.78
Debt-free, Cash-free Net Working Capital (DFCFNWC)	20	24	25	26	39	45	48	54	60	72	73
Debt-free Net Working Capital (DFNWC)	48	49	67	74	71	72	118	136	165	372	432
Net Working Capital (NWC)	48	49	67	74	71	69	118	136	165	372	432
Net Nonoperating Expense (NNE)	0.06	0.06	-0.00	-0.19	-0.41	1.11	1.68	-0.50	-2.11	-3.58	-5.58
Net Nonoperating Obligations (NNO)	-27	-24	-42	-48	-33	11	-70	-83	-105	-132	-190
Total Depreciation and Amortization (D&A)	3.39	3.59	4.06	4.32	5.42	8.40	11	9.43	9.52	9.67	11
Debt-free, Cash-free Net Working Capital to Revenue	25.99%	27.21%	25.24%	24.89%	32.89%	34.51%	31.16%	33.23%	30.83%	32.69%	29.16%
Debt-free Net Working Capital to Revenue	61.03%	54.45%	66.55%	70.34%	60.77%	55.36%	76.46%	84.38%	85.13%	169.01%	173.04%
Net Working Capital to Revenue	61.03%	54.45%	66.55%	70.34%	60.77%	53.43%	76.46%	84.38%	85.13%	169.01%	173.04%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.44	$0.57	$0.91	$1.18	$0.91	$1.05	$1.27	$0.94	$1.36	$1.96	$2.55
Adjusted Weighted Average Basic Shares Outstanding	17.76M	18.49M	18.96M	19.43M	19.81M	20.25M	21.16M	21.98M	22.22M	22.45M	22.64M
Adjusted Diluted Earnings per Share	$0.42	$0.55	$0.86	$1.13	$0.88	$1.04	$1.25	$0.93	$1.34	$1.93	$2.52
Adjusted Weighted Average Diluted Shares Outstanding	18.32M	19.24M	20.03M	20.24M	20.33M	20.48M	21.48M	22.17M	22.42M	22.78M	22.93M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	18.34M	18.67M	19.28M	18.67M	20.18M	20.53M	21.93M	22.10M	22.34M	22.56M	22.78M
Normalized Net Operating Profit after Tax (NOPAT)	7.57	11	17	17	18	22	29	22	28	40	52
Normalized NOPAT Margin	9.67%	11.95%	17.03%	15.84%	14.95%	16.98%	18.51%	13.90%	14.66%	18.40%	20.89%
Pre Tax Income Margin	14.58%	18.22%	20.92%	26.94%	18.49%	21.15%	22.20%	17.01%	20.40%	25.87%	30.12%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	1,155.36	997.52	13,907.50	0.00	21.72	16.36	0.00	0.00	254.30	12.98
NOPAT to Interest Expense	0.00	760.81	817.84	11,376.72	0.00	17.05	12.88	0.00	0.00	197.37	10.06
EBIT Less CapEx to Interest Expense	0.00	952.43	691.95	12,380.50	0.00	20.99	14.16	0.00	0.00	220.34	11.67
NOPAT Less CapEx to Interest Expense	0.00	557.88	512.26	9,849.72	0.00	16.31	10.68	0.00	0.00	163.41	8.75
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	36.67%	31.38%	24.33%	23.73%	37.56%	36.26%	34.70%	53.25%	41.35%	32.65%	31.37%
Augmented Payout Ratio	40.10%	34.32%	28.86%	26.96%	41.37%	38.95%	37.68%	56.36%	44.18%	36.55%	34.52%

This table displays calculated financial ratios and metrics derived from LeMaitre Vascular's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	22,778,363.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	22,778,363.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.69
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	21.48%	19.36%	13.60%	11.44%	15.63%	13.98%	11.95%	15.01%	11.36%	15.68%	11.16%
EBITDA Growth	38.65%	32.42%	44.67%	40.04%	38.56%	18.25%	7.07%	13.63%	43.38%	39.63%	33.14%
EBIT Growth	52.80%	40.40%	58.36%	49.10%	48.48%	22.24%	7.05%	14.06%	49.86%	44.67%	39.75%
NOPAT Growth	28.42%	51.90%	54.64%	47.85%	43.63%	34.26%	6.41%	12.23%	55.19%	40.98%	45.12%
Net Income Growth	37.50%	50.44%	63.69%	46.04%	48.51%	32.12%	11.37%	16.51%	55.84%	39.32%	42.39%
EPS Growth	32.00%	52.00%	62.96%	44.44%	48.48%	26.32%	9.09%	15.38%	53.06%	43.75%	41.67%
Operating Cash Flow Growth	61.03%	163.58%	122.51%	-19.14%	20.49%	41.28%	78.25%	110.82%	101.91%	52.53%	66.98%
Free Cash Flow Firm Growth	-152.41%	-91.35%	756.54%	53.23%	-77.27%	-805.02%	-242.99%	504.17%	436.70%	841.05%	724.42%
Invested Capital Growth	5.57%	3.94%	3.65%	6.60%	8.12%	6.49%	6.39%	2.41%	-1.40%	-1.12%	-2.23%
Revenue Q/Q Growth	-5.40%	3.10%	9.40%	4.43%	-1.84%	1.64%	7.46%	7.28%	-4.96%	5.58%	3.26%
EBITDA Q/Q Growth	-4.82%	12.10%	11.08%	18.16%	-5.83%	-4.32%	0.57%	25.41%	18.82%	-6.82%	-2.77%
EBIT Q/Q Growth	-6.70%	14.79%	14.29%	21.81%	-7.09%	-5.50%	0.10%	29.78%	22.07%	-8.77%	-3.30%
NOPAT Q/Q Growth	-5.51%	8.96%	20.13%	19.55%	-8.21%	1.85%	-4.79%	26.09%	26.92%	-7.47%	-1.99%
Net Income Q/Q Growth	-7.36%	12.84%	16.80%	19.61%	-5.79%	0.39%	-1.55%	25.14%	26.00%	-10.25%	0.62%
EPS Q/Q Growth	-8.33%	15.15%	15.79%	18.18%	-5.77%	-2.04%	0.00%	25.00%	25.00%	-8.00%	-1.45%
Operating Cash Flow Q/Q Growth	-0.67%	-9.11%	-52.81%	89.80%	48.01%	6.57%	-40.46%	124.48%	41.76%	-19.49%	-34.82%
Free Cash Flow Firm Q/Q Growth	20.10%	110.34%	560.74%	-185.69%	-202.86%	58.89%	-34.01%	342.23%	152.30%	-9.51%	12.92%
Invested Capital Q/Q Growth	-1.05%	0.63%	3.83%	3.11%	0.36%	-0.89%	3.73%	-0.75%	-3.36%	-0.61%	2.57%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	65.00%	68.05%	68.56%	68.88%	67.82%	69.26%	69.18%	70.02%	75.28%	71.66%	72.72%
EBITDA Margin	24.02%	26.11%	26.51%	30.00%	28.78%	27.09%	25.35%	29.64%	37.05%	32.70%	30.79%
Operating Margin	19.36%	20.88%	22.20%	25.75%	23.98%	23.07%	21.09%	25.13%	33.27%	29.22%	26.71%
EBIT Margin	18.96%	21.11%	22.06%	25.73%	24.35%	22.64%	21.09%	25.52%	32.77%	28.32%	26.52%
Profit (Net Income) Margin	15.82%	17.32%	18.49%	21.18%	20.32%	20.07%	18.39%	21.45%	28.44%	24.18%	23.56%
Tax Burden Percent	76.35%	74.83%	77.26%	76.27%	76.57%	79.77%	77.32%	76.25%	76.91%	76.76%	79.70%
Interest Burden Percent	109.29%	109.61%	108.49%	107.91%	109.00%	111.14%	112.77%	110.26%	112.83%	111.23%	111.47%
Effective Tax Rate	23.65%	25.17%	22.74%	23.73%	23.43%	20.23%	22.68%	23.75%	23.09%	23.24%	20.30%
Return on Invested Capital (ROIC)	14.70%	15.98%	17.43%	20.19%	19.62%	20.32%	17.86%	21.52%	29.96%	27.42%	25.90%
ROIC Less NNEP Spread (ROIC-NNEP)	14.15%	15.10%	16.68%	19.34%	18.65%	19.54%	16.83%	20.41%	28.80%	26.72%	24.99%
Return on Net Nonoperating Assets (RNNOA)	-4.55%	-5.01%	-5.42%	-6.52%	-6.65%	-7.29%	-6.23%	-7.91%	-12.11%	-11.79%	-11.03%
Return on Equity (ROE)	10.16%	10.97%	12.01%	13.67%	12.97%	13.03%	11.63%	13.61%	17.85%	15.63%	14.87%
Cash Return on Invested Capital (CROIC)	8.19%	10.93%	12.29%	11.00%	11.17%	14.04%	13.68%	17.91%	24.71%	26.67%	29.11%
Operating Return on Assets (OROA)	11.06%	12.43%	13.18%	15.34%	14.59%	11.08%	10.49%	12.73%	16.19%	12.11%	11.47%
Return on Assets (ROA)	9.23%	10.20%	11.05%	12.63%	12.18%	9.82%	9.15%	10.70%	14.05%	10.34%	10.19%
Return on Common Equity (ROCE)	10.16%	10.97%	12.01%	13.67%	12.97%	13.03%	11.63%	13.61%	17.85%	15.63%	14.87%
Return on Equity Simple (ROE_SIMPLE)	9.45%	0.00%	11.01%	11.79%	12.48%	0.00%	12.99%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	7.01	7.64	9.17	11	10	10	9.76	12	16	14	14
NOPAT Margin	14.78%	15.62%	17.15%	19.64%	18.36%	18.40%	16.31%	19.16%	25.59%	22.43%	21.29%
Net Nonoperating Expense Percent (NNEP)	0.56%	0.88%	0.75%	0.84%	0.97%	0.79%	1.03%	1.11%	1.17%	0.70%	0.91%
Return On Investment Capital (ROIC_SIMPLE)	-	2.56%	-	-	-	2.03%	1.89%	2.32%	2.85%	2.57%	2.46%
Cost of Revenue to Revenue	35.00%	31.95%	31.44%	31.12%	32.18%	30.74%	30.82%	29.98%	24.72%	28.34%	27.28%
SG&A Expenses to Revenue	16.32%	17.27%	16.85%	15.79%	16.30%	17.04%	17.52%	16.19%	17.61%	16.12%	18.10%
R&D to Revenue	8.91%	8.90%	7.65%	7.67%	6.67%	6.49%	6.84%	5.51%	4.87%	5.48%	6.10%
Operating Expenses to Revenue	45.63%	47.17%	46.36%	43.13%	43.84%	46.19%	48.09%	44.89%	42.01%	42.45%	46.01%
Earnings before Interest and Taxes (EBIT)	8.99	10	12	14	13	13	13	16	20	18	18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	11	13	14	17	16	15	15	19	23	21	20
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.16	4.21	4.79	5.77	6.30	6.14	5.45	5.17	5.23	4.68	6.12
Price to Tangible Book Value (P/TBV)	6.70	6.59	7.30	8.58	9.16	8.80	7.66	7.12	7.04	6.25	8.05
Price to Revenue (P/Rev)	6.48	6.48	7.39	8.96	9.80	9.42	8.37	8.00	8.22	7.37	9.70
Price to Earnings (P/E)	44.08	41.64	43.48	48.92	50.51	47.04	41.91	39.83	37.14	31.87	39.85
Dividend Yield	1.24%	0.99%	0.88%	0.73%	0.67%	0.69%	0.81%	0.87%	0.87%	0.99%	0.78%
Earnings Yield	2.27%	2.40%	2.30%	2.04%	1.98%	2.13%	2.39%	2.51%	2.69%	3.14%	2.51%
Enterprise Value to Invested Capital (EV/IC)	5.77	5.96	6.83	8.38	9.48	9.45	8.25	8.16	8.84	8.12	10.99
Enterprise Value to Revenue (EV/Rev)	5.95	5.94	6.84	8.41	9.22	8.82	7.77	7.35	7.50	6.61	8.93
Enterprise Value to EBITDA (EV/EBITDA)	25.82	25.02	27.20	31.41	33.01	31.39	27.99	26.51	25.11	20.99	27.35
Enterprise Value to EBIT (EV/EBIT)	33.05	31.56	33.58	38.04	39.39	37.21	33.20	31.38	29.31	24.52	31.65
Enterprise Value to NOPAT (EV/NOPAT)	43.53	41.02	43.80	49.74	51.88	47.94	42.83	40.70	37.68	31.63	40.46
Enterprise Value to Operating Cash Flow (EV/OCF)	36.73	31.25	34.60	46.43	49.47	43.96	36.56	29.36	24.65	20.30	26.21
Enterprise Value to Free Cash Flow (EV/FCFF)	72.35	55.53	56.58	78.65	88.14	69.41	62.22	46.11	35.54	30.29	37.33
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.50	0.48	0.46	0.44	0.43	0.42
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.50	0.48	0.46	0.44	0.43	0.42
Financial Leverage	-0.32	-0.33	-0.32	-0.34	-0.36	-0.37	-0.37	-0.39	-0.42	-0.44	-0.44
Leverage Ratio	1.16	1.16	1.15	1.14	1.15	1.41	1.39	1.38	1.37	1.60	1.57
Compound Leverage Factor	1.26	1.27	1.25	1.23	1.25	1.57	1.56	1.52	1.55	1.78	1.75
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	33.22%	32.58%	31.68%	30.77%	30.00%	29.34%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	33.22%	32.58%	31.68%	30.77%	30.00%	29.34%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	66.78%	67.42%	68.32%	69.23%	70.00%	70.66%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	2.71	2.67	2.58	2.34	2.15	2.02
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-2.14	-2.14	-2.32	-2.43	-2.42	-2.37
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	2.71	2.67	2.58	2.34	2.15	2.02
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	4.15	4.09	3.97	3.51	3.23	2.99
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-3.26	-3.28	-3.57	-3.64	-3.65	-3.51
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	4.15	4.09	3.97	3.51	3.23	2.99
Altman Z-Score	17.55	17.08	21.24	27.21	29.07	7.44	7.14	6.96	7.18	6.73	8.47
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.28	6.51	7.57	8.36	7.74	13.14	16.49	13.96	13.58	12.89	14.32
Quick Ratio	4.16	4.36	5.17	5.66	5.32	10.77	13.65	11.55	11.28	10.81	12.08
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-3.10	0.32	2.12	-1.82	-5.50	-2.26	-3.03	7.34	19	17	19
Operating Cash Flow to CapEx	1,122.79%	840.19%	370.15%	512.51%	853.05%	742.76%	653.58%	1,512.00%	1,261.03%	1,303.15%	542.33%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	-2.35	5.65	14.28	12.91	14.55
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	7.01	15.62	22.18	17.84	11.61
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	5.93	14.59	20.42	16.47	9.47
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.58	0.59	0.60	0.60	0.60	0.49	0.50	0.50	0.49	0.43	0.43
Accounts Receivable Turnover	8.44	8.22	7.19	7.19	7.59	7.98	6.92	6.97	7.45	7.84	7.23
Inventory Turnover	1.27	1.23	1.17	1.13	1.11	1.12	1.12	1.10	1.03	1.05	1.04
Fixed Asset Turnover	10.11	9.76	9.65	9.28	9.41	9.45	9.57	9.68	9.56	9.64	9.55
Accounts Payable Turnover	18.21	20.02	20.76	24.09	22.40	25.10	26.79	20.98	27.34	26.29	22.25
Days Sales Outstanding (DSO)	43.25	44.43	50.76	50.79	48.10	45.76	52.71	52.39	49.01	46.56	50.48
Days Inventory Outstanding (DIO)	288.53	297.65	311.23	322.92	327.94	325.52	326.95	332.53	354.46	347.60	352.60
Days Payable Outstanding (DPO)	20.05	18.23	17.58	15.15	16.29	14.54	13.62	17.40	13.35	13.89	16.40
Cash Conversion Cycle (CCC)	311.74	323.84	344.41	358.56	359.75	356.74	366.04	367.52	390.11	380.27	386.67
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	192	193	200	206	207	205	213	211	204	203	208
Invested Capital Turnover	0.99	1.02	1.02	1.03	1.07	1.10	1.10	1.12	1.17	1.22	1.22
Increase / (Decrease) in Invested Capital	10	7.32	7.06	13	16	13	13	4.97	-2.89	-2.30	-4.75
Enterprise Value (EV)	1,105	1,149	1,368	1,730	1,963	1,940	1,758	1,725	1,806	1,649	2,288
Market Capitalization	1,202	1,254	1,476	1,843	2,087	2,072	1,893	1,876	1,981	1,840	2,487
Book Value per Share	$12.96	$13.38	$13.81	$14.24	$14.73	$15.00	$15.41	$16.05	$16.74	$17.35	$17.85
Tangible Book Value per Share	$8.06	$8.55	$9.06	$9.57	$10.14	$10.48	$10.96	$11.67	$12.42	$12.98	$13.57
Total Capital	289	298	309	320	331	505	516	531	547	562	575
Total Debt	0.00	0.00	0.00	0.00	0.00	168	168	168	168	169	169
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	168	168	168	168	169	169
Net Debt	-97	-105	-108	-113	-124	-132	-135	-151	-175	-190	-198
Capital Expenditures (CapEx)	1.05	1.28	1.37	1.88	1.67	2.04	1.38	1.34	2.28	1.78	2.78
Debt-free, Cash-free Net Working Capital (DFCFNWC)	56	60	68	74	74	72	81	80	76	73	77
Debt-free Net Working Capital (DFNWC)	153	165	176	187	198	372	383	399	419	432	444
Net Working Capital (NWC)	153	165	176	187	198	372	383	399	419	432	444
Net Nonoperating Expense (NNE)	-0.49	-0.83	-0.71	-0.86	-1.07	-0.93	-1.25	-1.47	-1.74	-1.13	-1.51
Net Nonoperating Obligations (NNO)	-97	-105	-108	-113	-124	-132	-135	-151	-175	-190	-198
Total Depreciation and Amortization (D&A)	2.40	2.44	2.38	2.38	2.43	2.48	2.55	2.65	2.61	2.83	2.85
Debt-free, Cash-free Net Working Capital to Revenue	30.25%	30.83%	33.95%	36.12%	34.68%	32.69%	35.72%	34.02%	31.42%	29.16%	30.13%
Debt-free Net Working Capital to Revenue	82.54%	85.13%	88.13%	91.12%	92.84%	169.01%	169.44%	170.18%	173.85%	173.04%	173.42%
Net Working Capital to Revenue	82.54%	85.13%	88.13%	91.12%	92.84%	169.01%	169.44%	170.18%	173.85%	173.04%	173.42%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.34	$0.39	$0.44	$0.53	$0.50	$0.49	$0.49	$0.61	$0.77	$0.68	$0.69
Adjusted Weighted Average Basic Shares Outstanding	22.26M	22.22M	22.37M	22.46M	22.48M	22.45M	22.57M	22.61M	22.66M	22.64M	22.80M
Adjusted Diluted Earnings per Share	$0.33	$0.38	$0.44	$0.52	$0.49	$0.48	$0.48	$0.60	$0.75	$0.69	$0.68
Adjusted Weighted Average Diluted Shares Outstanding	22.48M	22.42M	22.57M	22.73M	22.84M	22.78M	22.90M	22.89M	24.39M	22.93M	23.03M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	22.26M	22.34M	22.45M	22.47M	22.48M	22.56M	22.59M	22.64M	22.69M	22.78M	22.85M
Normalized Net Operating Profit after Tax (NOPAT)	7.01	7.64	9.17	11	10	10	9.76	12	16	14	14
Normalized NOPAT Margin	14.78%	15.62%	17.15%	19.64%	18.36%	18.40%	16.31%	19.16%	25.59%	22.43%	21.29%
Pre Tax Income Margin	20.73%	23.14%	23.93%	27.76%	26.54%	25.16%	23.79%	28.13%	36.98%	31.50%	29.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	9.79	12.62	15.42	14.06	13.58
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	7.57	9.48	12.05	11.14	10.90
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	8.72	11.58	13.67	12.69	11.43
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	6.50	8.44	10.29	9.77	8.76
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	44.31%	41.35%	38.11%	35.60%	33.63%	32.65%	33.89%	34.45%	32.20%	31.37%	30.93%
Augmented Payout Ratio	46.79%	44.18%	41.17%	38.35%	36.13%	36.55%	38.24%	38.61%	35.87%	34.52%	33.63%

Financials Breakdown Chart

Key Financial Trends

Here are the key trends for LeMaitre Vascular (LMAT) based on the last four years of quarterly statements. The focus below is on actionable takeaways for retail investors, highlighting notable revenue, profitability, cash flow, and balance-sheet dynamics.

Revenue growth and margin stability: LMAT’s quarterly operating revenue rose to $64.45M in Q4 2025 from $55.72M in Q4 2024, representing roughly a 16% YoY increase. Gross profit for the same period was $46.19M, yielding an estimated gross margin of about 71.7%, up from about 69.2% a year earlier.
Profitable growth: Net income attributable to common shareholders climbed to $15.58M in Q4 2025 with a diluted EPS of $0.69 (vs. ~$0.48 in Q4 2024), signaling improving profitability alongside top-line growth. Operating income stood at $18.83M on revenue of $64.45M (roughly 29% operating margin).
Operating cash flow strength: Cash from continuing operating activities was $23.16M in Q4 2025, up from $15.18M in Q4 2024 and generally increasing through 2025 (e.g., Q1 2025 around $9.04M, Q2 around $20.29M, Q3 around $28.76M). This indicates solid, rising cash generation from core operations.
Liquidity and equity growth: The balance sheet shows ample liquidity, with sizable short-term investments (about $317.6M in Q3 2025) plus cash, and total equity expanding to around $379M by Q3 2025. Long-term debt remained manageable at roughly $168.2M, while total assets approached $598M in that period, signaling a stronger capital base.
Shareholder returns and consistent dividends: The company continued returning capital to shareholders via cash dividends per share of $0.20 per quarter, supporting income-focused investors while maintaining a strong equity position.
Debt level is steady but sizable: Long-term debt hovered in the mid-to-high $160M range (around $168M in mid-2025 quarters). While the debt level is not rapidly rising, it is a meaningful fixed obligation relative to quarterly cash flow, so keep monitoring leverage as operating cash flow fluctuates.
One-off investing activity in Q4 2025: Q4 2025 includes a notably large purchase of investments (about $598.3M), contributing to a pronounced investing outflow in that quarter. While the net cash from investing activities remained materially negative, the rest of 2025 showed more modest investing cash outflows, making this a potentially single, non-recurring item to watch for liquidity planning.
Investing cash flow volatility: In several quarters, net cash from investing activities was negative due to purchases of investments, acquisitions, and PPE, which can temporarily pressure liquidity if not offset by operating cash flow. For example, Q4 2025 shows a large, unusual outflow that needs context.
Financing activity drag and ongoing cash balance considerations: Net cash from financing activities was negative in multiple periods (driven by dividends, share repurchases, and other financing activities), contributing to fluctuations in overall cash position even as operating cash flow remained positive. This dynamic can impact the pace at which LMAT can deploy capital unrelated to operations.

05/17/26 07:43 PM ETAI Generated. May Contain Errors.

LeMaitre Vascular Financials - Frequently Asked Questions

According to the most recent income statement we have on file, LeMaitre Vascular's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

LeMaitre Vascular's net income appears to be on an upward trend, with a most recent value of $57.73 million in 2025, rising from $7.76 million in 2015. The previous period was $44.04 million in 2024. See where experts think LeMaitre Vascular is headed by visiting LeMaitre Vascular's forecast page.

LeMaitre Vascular's total operating income in 2025 was $67.91 million, based on the following breakdown:

Total Gross Profit: $178.54 million
Total Operating Expenses: $110.63 million

Over the last 10 years, LeMaitre Vascular's total revenue changed from $78.35 million in 2015 to $249.60 million in 2025, a change of 218.6%.

LeMaitre Vascular's total liabilities were at $222.17 million at the end of 2025, a 3.6% increase from 2024, and a 1,633.0% increase since 2015.

In the past 10 years, LeMaitre Vascular's cash and equivalents has ranged from $11.79 million in 2019 to $28.24 million in 2025, and is currently $28.24 million as of their latest financial filing in 2025.

Over the last 10 years, LeMaitre Vascular's book value per share changed from 4.30 in 2015 to 17.35 in 2025, a change of 303.5%.

Related Companies

Financial statements for NASDAQ:LMAT last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LeMaitre Vascular (LMAT) Financials

Financials Breakdown Chart

Key Financial Trends

LeMaitre Vascular Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LeMaitre Vascular (LMAT) Financials

Annual Income Statements for LeMaitre Vascular

Quarterly Income Statements for LeMaitre Vascular

Annual Cash Flow Statements for LeMaitre Vascular

Quarterly Cash Flow Statements for LeMaitre Vascular

Annual Balance Sheets for LeMaitre Vascular

Quarterly Balance Sheets for LeMaitre Vascular

Annual Metrics And Ratios for LeMaitre Vascular

Quarterly Metrics And Ratios for LeMaitre Vascular

Financials Breakdown Chart

Key Financial Trends

LeMaitre Vascular Financials - Frequently Asked Questions

When does LeMaitre Vascular's financial year end?

How has LeMaitre Vascular's net income changed over the last 10 years?

What is LeMaitre Vascular's operating income?

How has LeMaitre Vascular's revenue changed over the last 10 years?

How much debt does LeMaitre Vascular have?

How much cash does LeMaitre Vascular have?

How has LeMaitre Vascular's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools